JP2024532486A5 - - Google Patents
Info
- Publication number
- JP2024532486A5 JP2024532486A5 JP2024513938A JP2024513938A JP2024532486A5 JP 2024532486 A5 JP2024532486 A5 JP 2024532486A5 JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024532486 A5 JP2024532486 A5 JP 2024532486A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240189P | 2021-09-02 | 2021-09-02 | |
| US63/240,189 | 2021-09-02 | ||
| PCT/US2022/042429 WO2023034555A1 (en) | 2021-09-02 | 2022-09-02 | Antigen recognizing receptors targeting dll3 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532486A JP2024532486A (ja) | 2024-09-05 |
| JP2024532486A5 true JP2024532486A5 (https=) | 2025-09-10 |
Family
ID=85411573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513938A Pending JP2024532486A (ja) | 2021-09-02 | 2022-09-02 | Ｄｌｌ３を標的とする抗原認識受容体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240252640A1 (https=) |
| EP (1) | EP4396214A4 (https=) |
| JP (1) | JP2024532486A (https=) |
| CN (1) | CN118215675A (https=) |
| AU (1) | AU2022339815A1 (https=) |
| CA (1) | CA3230627A1 (https=) |
| WO (1) | WO2023034555A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| PH12021551720A1 (en) * | 2019-03-01 | 2022-03-28 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| CN113795262A (zh) * | 2019-04-08 | 2021-12-14 | 东莞凡恩世生物医药有限公司 | 人源化抗dll3嵌合抗原受体及其用途 |
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| EP4527466A3 (en) * | 2019-07-17 | 2025-06-18 | Legend Biotech Ireland Limited | Anti-dll3 chimeric antigen receptors and uses thereof |
-
2022
- 2022-09-02 AU AU2022339815A patent/AU2022339815A1/en active Pending
- 2022-09-02 CN CN202280072697.6A patent/CN118215675A/zh active Pending
- 2022-09-02 EP EP22865594.0A patent/EP4396214A4/en active Pending
- 2022-09-02 WO PCT/US2022/042429 patent/WO2023034555A1/en not_active Ceased
- 2022-09-02 JP JP2024513938A patent/JP2024532486A/ja active Pending
- 2022-09-02 CA CA3230627A patent/CA3230627A1/en active Pending
-
2024
- 2024-02-29 US US18/591,403 patent/US20240252640A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11292841B2 (en) | Anti-PD-1 nano-antibody and application thereof | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2024500847A5 (https=) | ||
| JP6426713B2 (ja) | Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球 | |
| JP2021512635A5 (https=) | ||
| US9200078B2 (en) | Antibodies against prostate-specific stem cell antigen and use thereof | |
| CN109942712A (zh) | 抗pd-l1/vegf双功能抗体及其用途 | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2020516276A5 (https=) | ||
| CN113784986B (zh) | 间皮素特异性嵌合抗原受体及表达它的t细胞 | |
| JP2024023228A5 (https=) | ||
| KR20180034430A (ko) | Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물 | |
| JP2022513372A5 (https=) | ||
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| KR20210021593A (ko) | 다양한 구조 최적화를 갖는 t 세포-항원 커플러 | |
| JP2024509910A5 (https=) | ||
| JP2025131589A (ja) | 固形腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 | |
| JP2022548112A5 (https=) | ||
| JP2025540340A (ja) | キメラ抗原受容体 | |
| JP2024532486A5 (https=) | ||
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| JP2024535740A5 (https=) | ||
| KR20230072536A (ko) | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 | |
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| JP2025513582A (ja) | Ｂｃｍａ細胞外ドメインをマーカーとする遺伝子、ポリペプチド、組換え発現ベクター、遺伝子操作された細胞及び当該遺伝子の使用 |